Pacific Edge eyes profitability after US Medicare breakthrough
Cancer diagnostics company Pacific Edge (ASX:PEB) reported its audited financial results for the 2026 financial year, marking a period of strategic transition highlighted by a crucial breakthrough in US Medicare policy.
The company announced the achievement of a new draft Local Coverage Determination, 'Urine-based Biomarkers in Patients with Microhematuria' (DL04378).
The milestone establishes haematuria evaluation as a Medicare benefit for the first time, covering both Cxbladder Triage and Triage Plus for intermediate-risk patients.
The inclusion of Triage Plus—which commands a higher Medicare price of US$1,328—is expected to bolster unit economics and accelerate the company's pathway to profitability.
Pacific Edge has also been cleared to pursue claim-by-claim reimbursement for the products ahead of the LCD becoming final, which is anticipated by the end of the 2026 calendar year.
Frequently asked questions
More from Australia
Capital battles heat up as takeover offers challenge listed housing operators
The equities fueling the next infrastructure supercycle
Crypto networks collide with sanctions in a fight for financial access
American Tungsten completes Nexus acquisition for Pinnacle MOU
Butn extends MYOB invoice financing agreement to 2027
Celsius Resources updates market on US$5M dispute
